CRISPR Therapeutics (CRSP) Announces Proposed 4.25M Common Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
CRISPR Therapeutics (CRSP) Prices 4.25M Share Common Offering at $64.50/Sh
November 21, 2019 5:52 AM ESTCRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 4,250,000 common shares at a public offering price of $64.50 per share. In addition, the underwriters have a 30-day... More
CRISPR Therapeutics (CRSP) PT Raised to $80 at Canaccord Genuity
November 19, 2019 3:20 PM ESTCanaccord Genuity analyst Arlinda Lee raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $80.00 (from $72.00) while maintaining a Buy rating.
... MoreWilliam Blair Upgrades CRISPR Therapeutics (CRSP) to Outperform
November 19, 2019 1:57 PM ESTWilliam Blair analyst Raju Prasad upgraded CRISPR Therapeutics (NASDAQ: CRSP) from Market Perform to Outperform.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $58.53 yesterday.
... MoreIncreasing unusual option volume: QGEN CRSP CSOD W FNV CCXI ASH DO CDK ATNX CLVS ESI MDCO NUAN ZTO NTR KSS
November 19, 2019 1:25 PM ESTIncreasing unusual option volume: QGEN CRSP CSOD W FNV CCXI ASH DO CDK ATNX CLVS ESI MDCO NUAN ZTO NTR KSS
... MoreCRISPR Therapeutics (CRSP) PT Raised to $75 at Goldman Sachs
November 19, 2019 1:00 PM ESTGoldman Sachs analyst Salveen Richter raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $75.00 (from $52.00) while maintaining a Neutral rating.
... MoreCRISPR Therapeutics (CRSP) PT Raised to $100 at Roth Capital
November 19, 2019 11:50 AM ESTRoth Capital analyst Tony Butler raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $100.00 (from $65.00) while maintaining a Buy rating.
... MoreCRISPR Therapeutics (CRSP) PT Raised to $84 at Needham & Company
November 19, 2019 11:32 AM ESTNeedham & Company analyst Alan Carr raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $84.00 (from $62.00) while maintaining a Buy rating.
... MoreCRISPR Therapeutics (CRSP), Vertex (VRTX) Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobino
November 19, 2019 7:02 AM ESTCRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced positive, interim data from the first two patients with severe hemoglobinopathies treated with... More
CRISPR Therapeutics (CRSP) PT Raised to $28 at Citi
November 18, 2019 6:17 AM ESTCiti analyst Yigal Nochomovitz raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $28.00 (from $21.00) while maintaining a Sell rating.... More
